F. NostenF. Ter KuileL. MaelankiriT. ChongsuphajaisiddhiL. NopdonrattakoonS. TangkitchotE. BoudreauD. BunnagN. J. WhiteShoklo Malaria Research UnitMahidol UniversityAcademic Medical Centre, University of AmsterdamPharmaceutical Systems Inc.John Radcliffe Hospital2018-02-272018-02-271994-01-01Journal of Infectious Diseases. Vol.169, No.3 (1994), 595-60315376613002218992-s2.0-0028009814https://repository.li.mahidol.ac.th/handle/123456789/9846A double-blind, placebo-controlled study of mefloquine antimalarial prophylaxis in pregnancy ( > 20 weeks of gestation) was conducted in 339 Karen women living in an area of multidrug-resistant malaria transmission on the Thai-Burmese border. Mefloquine gave ≥86% (95% confidence interval [CI], 59%-94%) protection against Plasmodium falciparum and complete protection against Plasmodium vivax infections. Mefloquine prophylaxis was welltolerated; use of an initial loading dose (10 mg/kg) was associated with transient dizziness, but there were no other significant adverse effectson the mother, the pregnancy, or infant survivalor development(followed for 2 years). Falciparum malaria was associated with maternal anemia and a mean reduction in birth weight in gravidae I, II, and III of225 g (95%CI, 26-423). Maternal anemia at delivery(hematocrit < 30%) was associated with increased infant mortality: 26% versus 15% (relative risk, 1.9; 95% CI, 1.1-3.2). Mefloquine is safe and effective for antimalarial prophylaxis in the second half of pregnancy. © 1994 by The University of Chicago.Mahidol UniversityMedicineArticleSCOPUS10.1093/infdis/169.3.595